Aimmune says US government shutdown stymied its peanut allergy drug application
As the longest government shutdown in US history endures the wrath of lawmakers on either side of the aisle, Aimmune Therapeutics $AIMT will bear the brunt of stretched funds at the FDA. Company management — who submitted their application to market their peanut allergy drug one day preceding the shutdown — on Monday said the health regulator had notified them that it would not be able to review the application until the lapse in appropriations ends.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.